SEARCH RESULTS FOR: "Tag: INMB"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2019(1)
CATEGORIES
Analyst Update(1)

8/21/2019 11:21 AM
H.C. Wainwright initiated coverage on INmune Bio Inc (NASDAQ:INMB) with a "buy" rating and an $11.50 price target -- a nearly 94% premium to last night's close. The analyst in coverage expects the Ca...
PEOPLE ALSO SEARCH FOR
Partner Center